232 related articles for article (PubMed ID: 29424790)
1. Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel.
Thurman AR; Chandra N; Yousefieh N; Kimble T; Anderson SM; Cottrell M; Sykes C; Kashuba A; Schwartz JL; Doncel GF
J Acquir Immune Defic Syndr; 2018 May; 78(1):82-92. PubMed ID: 29424790
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Justman JE; Nair GL; Hendrix CW; Piper JM; Marzinke MA; Dai JY; Pan Z; Galaska B; Levy L; Schwartz JL; Balar B; Kunjara Na Ayudhya RP; Mushamiri I; McGowan I; Dezzutti CS;
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):175-182. PubMed ID: 29767639
[TBL] [Abstract][Full Text] [Related]
3. Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
Thurman AR; Schwartz JL; Ravel J; Gajer P; Marzinke MA; Yousefieh N; Anderson SM; Doncel GF
PLoS One; 2019; 14(5):e0217229. PubMed ID: 31107913
[TBL] [Abstract][Full Text] [Related]
4. Effect of Hormonal Contraception on Pharmacokinetics of Vaginal Tenofovir in Healthy Women: Increased Tenofovir Diphosphate in Injectable Depot Medroxyprogesterone Acetate Users.
Thurman AR; Schwartz JL; Brache V; Chen BA; Chandra N; Kashuba ADM; Weiner DH; Mauck C; Doncel GF
J Acquir Immune Defic Syndr; 2019 Jan; 80(1):79-88. PubMed ID: 30212395
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women.
Burns RN; Hendrix CW; Chaturvedula A
J Clin Pharmacol; 2015 Jun; 55(6):629-38. PubMed ID: 25581815
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05).
Robinson JA; Marzinke MA; Fuchs EJ; Bakshi RP; Spiegel HML; Coleman JS; Rohan LC; Hendrix CW
J Acquir Immune Defic Syndr; 2018 Feb; 77(2):175-182. PubMed ID: 29135651
[TBL] [Abstract][Full Text] [Related]
7. FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir.
Bunge KE; Dezzutti CS; Hendrix CW; Marzinke MA; Spiegel HML; Moncla BJ; Schwartz JL; Meyn LA; Richardson-Harman N; Rohan LC; Hillier SL
J Int AIDS Soc; 2018 Aug; 21(8):e25156. PubMed ID: 30101439
[TBL] [Abstract][Full Text] [Related]
8. Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel.
Gao Y; Katz DF
PLoS One; 2013; 8(9):e74404. PubMed ID: 24040241
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits.
Clark MR; Friend DR
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1458-66. PubMed ID: 22394281
[TBL] [Abstract][Full Text] [Related]
10. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
Dobard C; Sharma S; Martin A; Pau CP; Holder A; Kuklenyik Z; Lipscomb J; Hanson DL; Smith J; Novembre FJ; García-Lerma JG; Heneine W
J Virol; 2012 Jan; 86(2):718-25. PubMed ID: 22072766
[TBL] [Abstract][Full Text] [Related]
11. A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.
Johnson TJ; Clark MR; Albright TH; Nebeker JS; Tuitupou AL; Clark JT; Fabian J; McCabe RT; Chandra N; Doncel GF; Friend DR; Kiser PF
Antimicrob Agents Chemother; 2012 Dec; 56(12):6272-83. PubMed ID: 23006751
[TBL] [Abstract][Full Text] [Related]
12. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.
Anton PA; Cranston RD; Kashuba A; Hendrix CW; Bumpus NN; Richardson-Harman N; Elliott J; Janocko L; Khanukhova E; Dennis R; Cumberland WG; Ju C; Carballo-Diéguez A; Mauck C; McGowan I
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1412-21. PubMed ID: 22943559
[TBL] [Abstract][Full Text] [Related]
13. Topical tenofovir protects against vaginal simian HIV infection in macaques coinfected with Chlamydia trachomatis and Trichomonas vaginalis.
Makarova N; Henning T; Taylor A; Dinh C; Lipscomb J; Aubert R; Hanson D; Phillips C; Papp J; Mitchell J; McNicholl J; Garcia-Lerma GJ; Heneine W; Kersh E; Dobard C
AIDS; 2017 Mar; 31(6):745-752. PubMed ID: 28060011
[TBL] [Abstract][Full Text] [Related]
14. Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring.
Thurman AR; Ravel J; Gajer P; Marzinke MA; Ouattara LA; Jacot T; Peet MM; Clark MR; Doncel GF
Front Cell Infect Microbiol; 2022; 12():799501. PubMed ID: 35350436
[TBL] [Abstract][Full Text] [Related]
15. Short Communication: Specimen Processing Impacts Tissue Tenofovir Pharmacokinetic Measurements.
Bakshi RP; Breakey J; Manohar M; Jois B; Fuchs EJ; Marzinke MA
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):354-356. PubMed ID: 29258331
[TBL] [Abstract][Full Text] [Related]
16. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel.
Schwartz JL; Rountree W; Kashuba AD; Brache V; Creinin MD; Poindexter A; Kearney BP
PLoS One; 2011; 6(10):e25974. PubMed ID: 22039430
[TBL] [Abstract][Full Text] [Related]
17. Vaginal deployment and tenofovir delivery by microbicide gels.
Gao Y; Yuan A; Chuchuen O; Ham A; Yang KH; Katz DF
Drug Deliv Transl Res; 2015 Jun; 5(3):279-94. PubMed ID: 25874971
[TBL] [Abstract][Full Text] [Related]
18. A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir.
Thurman AR; Ouattara LA; Yousefieh N; Anderson PL; Bushman LR; Fang X; Hanif H; Clark M; Singh O; Doncel GF
Front Cell Infect Microbiol; 2023; 13():1130101. PubMed ID: 37153145
[TBL] [Abstract][Full Text] [Related]
19. Effects of gel volume on pharmacokinetics for vaginal and rectal applications of combination DuoGel-IQB4012, a dual chamber-dual drug HIV microbicide gel, in pigtailed macaques.
Pereira LE; Singletary T; Martin A; Dinh CT; Deyounks F; Holder A; McNicholl J; Buckheit KW; Buckheit RW; Ham A; Katz DF; Smith JM
Drug Deliv Transl Res; 2018 Oct; 8(5):1180-1190. PubMed ID: 29761350
[TBL] [Abstract][Full Text] [Related]
20. A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.
Yang KH; Hendrix C; Bumpus N; Elliott J; Tanner K; Mauck C; Cranston R; McGowan I; Richardson-Harman N; Anton PA; Kashuba AD
PLoS One; 2014; 9(10):e106196. PubMed ID: 25350119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
